データなし
コード銘柄名
現在値変化額変化率出来高売買代金始値前日終値高値安値時価総額浮動株時価株式総数浮動株5日変化率10日変化率20日変化率60日変化率120日変化率250日変化率年初来配当利回売買回転率直近PER前年PER振幅業種
お気に入り
データなし
CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
CytomX Therapeutics Announces First Patient Dosed With CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY, in a Phase 1 Study in Patients With Solid Tumors
CytomX Therapeutics to Present at Upcoming September Investor Conferences
CytomX Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
CytomX Therapeutics Files $250M Mixed Securities Shelf
Earnings Call Summary | CytomX(CTMX.US) Q2 2024 Earnings Conference
データなし
データなし